Immunovia AB, a biotechnology company specializing in the development of blood-based tests for early detection of cancer, has announced the appointment of Jeff Borcherding as its new global CEO. Borcherding, who has been President of Immunovia’s US operation since April 2022, will replace Philipp Matthieu as the Company shifts its focus to the United States market and commercializing its flagship product, IMMray™ PanCan-d.
Jeff Borcherding’s Career Path: From Diagnostics to Immunovia
Having led Immunovia’s US business for over a year, Borcherding brings a wealth of experience to his new role as global CEO. Before joining the Company, he held various positions within the American diagnostics industry, including Chief Marketing Officer at Myriad Genetics. As he takes on this new global responsibility, Borcherding will continue to spearhead Immunovia’s US business.
Streamlining Management: A Strategic Move
This management change is a strategic move by Immunovia to simplify and streamline its organizational structure. The company’s primary focus is the commercialization of IMMray™ PanCan-d, the first blood-based test dedicated to early detection of pancreatic cancer, in the United States. By appointing Borcherding as global CEO, Immunovia aims to strengthen its foothold in the US market and accelerate the adoption of its innovative diagnostic tool.
Philipp Matthieu’s Contributions: Restructuring and Refocusing
Professor Carl Borrebaeck, chair of the Board of Directors, expressed his gratitude to outgoing CEO Philipp Matthieu for his dedication and support during his tenure. Matthieu oversaw a crucial restructuring of the Swedish operations, which resulted in a more focused approach to the successful commercialization of Immunovia’s unique product. He also played a pivotal role in recruiting strong technical leadership for the Swedish operations, ultimately making the role of a Swedish-based CEO redundant.
Jeff Borcherding’s Vision: A High-Growth Future
In his new role as global CEO, Borcherding is enthusiastic about leading Immunovia to capitalize on the tremendous opportunity to revolutionize early detection of pancreatic cancer. He is committed to building a successful, high-growth business that will ultimately improve patient outcomes by detecting this deadly disease at an earlier stage.
Transition Period: Ensuring a Smooth Handover
To ensure a smooth transition, Philipp Matthieu will remain at the Board of Directors’ disposal during his six-month notice period, which begins today. This will allow Borcherding to seamlessly take over the reins of the Company and continue driving its mission to revolutionize early cancer detection.
IMMray™ PanCan-d: A Game Changer in Cancer Detection
As the first blood-based test dedicated to early detection of pancreatic cancer, IMMray™ PanCan-d represents a significant breakthrough in cancer diagnostics. By focusing on the US market, Immunovia aims to make this innovative test widely available, potentially saving countless lives by identifying pancreatic cancer at an earlier, more treatable stage.
Challenges Ahead: Navigating the US Market
Despite the promising potential of IMMray™ PanCan-d, Immunovia will face challenges in navigating the complex US healthcare system. The company will need to secure regulatory approval, forge strategic partnerships, and establish a robust distribution network to ensure the widespread adoption of its groundbreaking diagnostic tool.
Conclusion: Immunovia’s Bold Vision
The appointment of Jeff Borcherding as global CEO marks a significant milestone for Immunovia, as it seeks to revolutionize pancreatic cancer detection in the United States. With his extensive experience in the diagnostics industry and proven leadership abilities, Borcherding is poised to drive the company’s growth and bring its pioneering IMMray™ PanCan-d test to the forefront of cancer diagnostics. As Immunovia streamlines its management structure and refocuses its efforts on the US market, it is well-positioned to make a significant impact on early cancer detection and ultimately improve patient outcomes. In a rapidly evolving healthcare landscape, the company’s bold vision and innovative approach hold the potential to transform the lives of millions affected by pancreatic cancer.